FIELD: pharmacy.
SUBSTANCE: invention relates to the field of pharmacy, namely to an aqueous composition with an anti-glioblastoma effect. The aqueous composition with an anti-glioblastoma effect contains lithium citric acid tetrahydrate and melatonin, while a lithium citrate content in the composition is 0.03-0.125 mg/ml, and a melatonin content is 0.003-0.015 mg/ml.
EFFECT: above-mentioned composition is characterized by a synergetic effect consisting in reduction in viability of glioma cells due to lithium and preservation of viability of fibroblast cells under action of lithium due to melatonin.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF APPLYING TRANS-RESVERATROLE NANO-FORM FOR TREATMENT AND PREVENTION OF HORMONE-DEPENDENT PROLIFERATIVE PROCESSES, INCLUDING TUMOURS | 2009 |
|
RU2428974C2 |
| 1,1'-(HEXANE-1,6-DIYL)BIS(3-(((1R,4AS,10AR)-7-ISOPROPYL-1,4A-DIMETHYL-1,2,3,4,4A,9,10,10A-OCTAHYDROPHENANTAREN-1-YL)METHYL)UREA, WHICH EXHIBITS INHIBITING ACTION ON HUMAN TYROSYL-DNA-PHOSPHODIESTERASE 1 ENZYME AND INCREASES TEMOZOLOMIDE ACTIVITY ON GLIOBLASTOMA CELLS | 2019 |
|
RU2724882C1 |
| 1-ADAMANTYL-3-(((1R,4AS,10AR)-7-ISOPROPYL-1,4A-DIMETHYL-1,2,3,4,4A,9,10,10A-OCTAHYDROPHENANTHREN-1-YL)METHYL)UREA, WHICH EXHIBITS INHIBITING ACTION ON HUMAN TYROSYL-DNA-PHOSPHODIESTERASE 1 ENZYME AND INCREASES ACTIVITY OF TEMOZOLOMIDE AGAINST GLIOBLASTOMA CELLS | 2019 |
|
RU2697409C1 |
| AGENT POSSESSING CYTOTOXIC ACTIVITY WITH RESPECT TO U87MG GLIOMA CELL CULTURE | 2024 |
|
RU2839886C1 |
| METHOD FOR PROPHYLACTIC TREATMENT IN CASE OFNEOPLASTIC PROCESSES INVOLVING SKIN TISSUE, SUCH AS MELANOMA, BASAL CELL AND SQUAMOUS CELL CARCINOMA | 2015 |
|
RU2619208C2 |
| NIDO-CARBORAN-CONTAINING FOLIC ACID BIS-AMIDES FOR BORON DELIVERY TO TUMOR CELLS | 2022 |
|
RU2794768C1 |
| ANTI-TUMOUR COMPOSITION BASED ON HYALURONIC ACID AND INORGANIC NANOPARTICLES, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2015 |
|
RU2686679C2 |
| TUMOUR CELL RADIOSENSITIZATION METHOD | 2024 |
|
RU2834199C1 |
| COMBINED CHEMOTHERAPY AND IMMUNOTHERAPY | 2006 |
|
RU2473560C2 |
| ANTITUMOR TARGET CELL PRODUCT, METHOD FOR ITS PRODUCTION AND ITS APPLICATION | 2018 |
|
RU2757812C2 |
